An observational study in Diabetic Retinopathy and Type 2 Diabetes Mellitus (T2DM), sponsored by University of Chile. Completed at 1 site in Chile. Open to participants aged 30 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by University of Chile · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational study is to learn if automated pupillometry (AP)-a simple tool that measures how the eye responds to a brief light stimulus-can help diagnose diabetic retinopathy (DR), a complication of diabetes that can lead to blindness, in people with type 2 diabetes (T2DM).
The main question it aims to answer is:
DR usually has no symptoms in its early stages, so early screening is crucial to prevent progression to blindness. Participants in this study will undergo two tests:
Patients will undergo a clinical evaluation, AP assessment, and FE during the same visit. AP will be performed to obtain three valid trials per eye using a clinical pupilometer. For DR diagnosis, pupil-dilated eye fundus images will be captured with a retinal camera and subsequently interpreted by an ophthalmologist. Both patients and AP/FE operators will remain blinded to the FE/AP data.
781 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.
This study's enrollment of 240 is above the median of 173 across 265 observational studies indexed under Diabetic Retinopathy.
Browse Diabetic Retinopathy studies →University of Chile is the lead sponsor of 195 studies on the registry; 38 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with type 2 diabetes (T2DM) from all three public primary care health centers in the municipality of Independencia (Santiago, Chile), who are on the waiting list for fundoscopic examination (FE) to screen for diabetic retinopathy (DR).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patient with diabetic retinopathy diagnosed through fundoscopic examination
Patient without diabetic retinopathy on fundoscopic examination.
Diagnostic accuracy of automated pupillometry (AP) for diabetic retinopathy (DR) screening
The diagnostic accuracy of AP for DR will be evaluated by the area under the curve (AUC), sensitivity, specificity and predictive values.
Time frame: At baseline (study enrollment)
Prevalence of diabetic retinopathy in the study sample
Frequency (%) of participants with diabetic retinopathy in the sample
Time frame: At baseline (study enrollment)
Risk factors for diabetic retinopathy
Clinical factors statistically related with diabetic retinopathy presence
Time frame: At baseline (study enrollment)
Ran from Jan 2023 to primary completion in Aug 2023, 6 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.